Biodexa Pharmaceuticals Plc
Close on Oct 19, 2026
About Biodexa Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Biodexa Pharmaceuticals plc is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics. The company specializes in identifying, acquiring, and advancing clinical pharmaceutical assets, particularly targeting therapeutic indications with significant unmet medical needs. Its research and development initiatives encompass multiple proprietary pipeline programs, including MTX228 Tolimidone, MTX230 eRapa, and related investigational drug candidates. Through targeted clinical and laboratory efforts, the business directs its pipeline development toward advancing specialty treatment options.
The company conducts its clinical and administrative activities across several operational regions. Its global footprint is represented through subsidiaries and activities spanning the United Kingdom, the United States, Australia, and Ireland, alongside documented commercial exposures in Belgium. The parent entity, Biodexa Pharmaceuticals plc, is registered and maintains its primary corporate headquarters within the United Kingdom.
Summary of the business section of Biodexa Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Biodexa Pharmaceuticals Plc
- Headquarters
- Cardiff, United Kingdom
- Address
- 1 Caspian Point, Caspian Way CF10 4DQ
- Phone
- 44 (0)1235 888300
- Website
- biodexapharma.com
- Employees
- 12, Dec 31, 2018
- Industry
- Pharmaceutical Preparations
- Incorporated in
- X0
- Fiscal year ends
- December 31
- Auditor
- Mazars LLP, London, England
Stock & identifiers
- Ticker
- BDRX
- Exchange
- Nasdaq
- IPO date
- Dec 7, 2015
- Shares outstanding
- 225.82B, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-5 reverse, Apr 6, 2026; 1-for-10 reverse, Jul 31, 2025; 1-for-25 reverse, Oct 4, 2024; 1-for-80 reverse, Jul 5, 2023; 1-for-20 reverse, Apr 28, 2023; 1-for-4 reverse, Mar 27, 2023; 1-for-5 reverse, Sep 26, 2022; 1-for-20 reverse, Jun 15, 2020; 1-for-5 reverse, Mar 3, 2020; 1-for-10 reverse, Apr 8, 2019
- SEC CIK
- 1643918
- CUSIP
- 59564R872
- ISIN
- US59564R8723
- LEI
- 549300GKR2G40H3QFY57
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Fiona Mary Powell | Chief Financial Officer, Director | – |
| Stephen Anthony Stamp | Chief Executive Officer, Director | – |
| Stephen Barry Parker | Director | – |
| Ann Louise Merchant | Director | – |
| Simon Turton | Director | 2,765 |
| Vries Simon de | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 27, 2023 | Name change | Name changed from Midatech Pharma Plc to Biodexa Pharmaceuticals Plc |
| Dec 2, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 11, 2015 | Merger | Registration of securities for a merger or exchange offer (S-4) |